> The FDA has granted ViroPharma fast track status for its transplant antivirus drug maribavir. The therapy is in mid-stage trials with the Exton, PA-based developer expected to release data by the end of this quarter. Report
> New River Pharmaceuticals has pocketed a $50 million milestone payment from Shire based on the Phase I/II data for its experimental pain drug NRP290. Release
> Nabi Biopharmaceuticals announced positive data from Phase I studies of the company's S. epidermidis PS-1 vaccine and its S. aureus Type 336 vaccine. Release
> Roche says it will halt sales of the HIV drug Fortovase in favor of another, more convenient medication. Report
> Ciphergen has inked a research pact with Sanofi-Aventis to seek biomarkers for a pre-clinical drug efficacy study in the field of oncology. Release
> Optimer's lead antibiotic therapy is headed into a Phase IIb/III trial for Clostridium difficile-associated diarrhea. Release
And Finally... New research indicates that your cardiovascular risk factors at age 50 will have a major impact on your life expectancy. Report